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Abstract
Introduction: Fabry disease is an X-linked lysosomal storage disorder resulting in a multiple-system disorder with a
wide spectrum of physical signs and symptoms, predominantly affecting the central and peripheral nervous
systems, skin, heart, kidneys, and eyes.
Case presentation: We describe the case of a 26-year-old European Caucasian man who had Fabry disease and
who presented with episodic sudden unilateral hearing loss and was treated with glucocorticoids, pentoxifylline,
hyperbaric oxygen, and fluoride because of concomitant audiometric evidence of otosclerosis. This case
demonstrates the partial and transient beneficial effect of standard treatment for sudden hearing loss not related
to Fabry disease and analyzes the possible connection between typical Fabry disease inner-ear lesions and
otosclerosis. Whereas hearing loss has been described in connection with Fabry disease, otosclerosis-associated
hearing loss in Fabry disease has not yet been described.
Conclusions: Although progressive hearing loss in patients with Fabry disease seems to be influenced by
replacement therapy, few data concerning treatment of sudden hearing loss are available. The lack of literature
concerning the pathogenesis of the otological involvement in Fabry disease makes it impossible to identify a
connection between the latter and otosclerosis. Therefore, this report may help to reinforce the importance of a
thorough evaluation of hearing in patients with Fabry disease and may be of help with therapeutic decision-
making.
Introduction
Fabry disease (FD) is an X-linked lysosomal storage dis-
order that is due to the deficient activity of the enzyme
alpha-galactosidase A (GLA enzyme), a lysosomal
hydrolase encoded by the alpha-galactosidase gene (GLA
gene; EC 3.2.1.22) [1]. This enzyme deficiency leads to
widespread deposition of neutral glycosphingolipids
(mainly globotriaosylceramide and, to a lesser extent,
galabiosylceramide) on blood vessel walls throughout
the body, resulting in a multiple-system disorder with a
wide spectrum of physical signs and symptoms that pre-
dominantly affect the central and peripheral nervous
systems, skin, heart, kidneys, and eyes. Acroparesthesias
and pain crises, hypohydrosis, angiokeratomas, and cor-
neal dystrophy are among the typical initial manifesta-
tions, whereas cardiomyopathy, renal failure, and
cerebrovascular events dominate in patients with FD [2].
The otorhinolaryngological area is not spared by this
disease, and the majority of patients develop progressive
and accelerated sensorineural hearing loss (SNHL) dur-
ing adulthood [3]. Also, a high incidence of vestibular
disorders with dizziness and chronic instability is
observed in these patients [4].
Otosclerosis (incidence of 0.3% to 0.4% in Caucasians)
[5] is a bone remodeling disorder of the human otic
capsule; however, the etiopathogenesis remains unclear.
Genetic predisposition, disturbed bone metabolism, per-
sistent measles virus infection, autoimmunity, and hor-
monal and environmental factors may play contributing
roles in the pathogenesis of otosclerosis. Clinical signs
are progressive conductive hearing loss or SNHL (or
both) as a consequence of stapes footplate fixation and
cochlear bone resorption with endosteal involvement.
Instrumental examinations (audiometry, impedensitome-
try, and computed tomography) aid in identifying
affected patients, but a definitive diagnosis can be
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We describe the case of a 26-year-old Caucasian man
who had FD and who presented after two episodes of
unilateral sudden hearing loss (SHL) and who was trea-
ted with glucocorticoids, pentoxifylline, and hyperbaric
oxygen without complete recovery of right ear function.
The case was associated with the audiometric character-
istics of otosclerosis.
Case presentation
A 26-year-old Caucasian man tested positive for FD
when he was nine years old. At presentation, his main
manifestations were fatigue, hypohydrosis, and painful
acroparesthesias correlated with fever and physical
effort.. The dosage of GLA activity in lymphocytes was
2.4 nmol/hour per mg, which was well below normal
v a l u e s( 2 4t o5 6n m o l / h o u rp e rm gp r o t e i n ) ,a n da
molecular genetic analysis confirmed the diagnosis
(R100K mutation in exon 2). Our patient was in good
health until 18 years of age, when he had three episodes
of severe nephrotic syndrome and acute renal failure
requiring hospitalization and corticotherapy. Enzyme
replacement therapy (ERT) with agalsidase-b (Fabra-
zyme
®; Genzyme Corporation, Cambridge, MA, USA),
at a dosage of 1 mg/kg intravenously every 2 weeks, was
started in 2001 after approval of the drug in Italy. Since
then, his renal function has been stable. Before the start
of ERT, the brain (evaluated by magnetic resonance
imaging), fundus oculi, cardiac function and morphol-
ogy, hearing, and kidney function were evaluated, and
all were normal.
Almost four years ago, our patient complained of diz-
ziness lasting 30 to 40 minutes with spontaneous regres-
sion associated with left-sided SHL (as defined by
Hughes and colleagues [6]) and tinnitus. The results of
a neurological examination were normal, as were those
of an audiogram performed a few weeks before the
onset of symptoms. Also, our patient had no history of
SHL, otosclerosis, or any other auditory disease in his
family.
We then performed an audiometric test, which
showed a left SNHL associated with a mild conductive
component at low frequencies (Figure 1) and a normal
(type A) tympanogram without stapedial reflexes (ipsi-
lateral and contralateral) with the probe in the left ear.
The result of pure-tone audiometry was normal in the
right ear. Further examination showed vestibular suffer-
ing of ischemic etiology in all likelihood and a left-beat-
ing nystagmus revealed only by the head-shaking test
and increased by lateral decubitus.
An otological investigation revealed normal tympanic
membranes. The brainstem auditory evoked response
was consistent with the auditory impairment, showing
increased latencies for the central pathways of the left
ear, and an augmented I-V interval was on the left side.
Figure 1 Left sensorineural hearing loss associated with a mild conductive component on low frequencies after the onset of
symptoms. Blue cross, left ear conduction; blue open arrow, left ear bone conduction; blue square, left ear conduction with narrow band note
masking on the opposite ear; blue triangle, left ear bone conduction with narrow band note masking on the opposite ear; red circle, right ear air
conduction; red open arrow, right ear bone conduction.
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Oral corticosteroid therapy with prednisone (50 mg/
day for two days decreased to 25 mg every two days for
eight days) along with hyperbaric oxygen therapy was
administered for eight days; our patient underwent eight
sessions of 80 minutes each at 1.5 bars of pressure with
100% oxygen. Audiometry was performed after eight
days and showed mild recovery of both the bone and air
conduction. However, our patient continued to com-
plain of left-ear hearing loss associated with intense tin-
nitus. This prompted us to continue therapy by
performing a second cycle of hyperbaric oxygen treat-
ment with the addition of oral pentoxifylline (400 mg
twice per day for 15 days) as an anti-aggregant. Our
patient reported subjective improvement of the tinnitus
after the fifth session. An ear, nose, and throat evalua-
tion after the completion of therapy showed an almost
complete normalization of bone conduction and only a
mild deficit, whereas a conductive gap on low frequen-
cies remained (Figure 2), calling into question the purely
vascular origin of the hearing loss. The brain and cere-
bellopontine angle were examined by magnetic reso-
nance imaging to detect the persistence of the left
interventricular trigonal lesion, present for six years, and
a new malacic lesion at the left thalamic site.
Our patient experienced a new SHL crisis and tinnitus
about eight months later. An audiogram showed a
decrease in hearing function for frequencies of 2 to 8
kHz, but the conductive gap was unchanged (Figure 3).
Our patient presented a type A tympanogram with no
evocable stapedial reflexes on the left side.
As the audiometric pattern resembled that of oto-
sclerosis, we performed a fine-slice computed tomogra-
phy scan to study the oval window, but no alterations
Figure 2 Almost complete normalization of bone conduction with only a mild deficit (threshold of 25dBnHL at 1 to 2 kHz). An air-bone
gap on low frequencies remained after therapy. Blue cross, left ear conduction; blue open arrow, left ear bone conduction; blue square, left ear
conduction with narrow band note masking on the opposite ear; blue triangle, left ear bone conduction with narrow band note masking on the
opposite ear; red circle, right ear air conduction; red open arrow, right ear bone conduction.
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(prednisone and pentoxifylline) and hyperoxygen ther-
apy with the addition of sodium fluoride (30 mg/day
orally) for two months to slow down the evolution of
the suspected otosclerosis.
Repeated audiograms performed after five days and
one month showed no significant recovery, whereas the
audiogram performed three months after the onset of
the hearing loss showed partial recovery of high-fre-
quency hearing (Figure 4). However, the conductive
component did not change and the suspicion of oto-
sclerosis remained.
Given the increased risk of stroke and microvascular
disease, our patient began permanent therapy with
acetyl salicylic acid at a dosage of 300 mg/day. Brain-
stem auditory evoked potentials performed during and
three months after the second episode showed mild suf-
fering of the central auditory pathway on the left. Minor
SNHL with associated conductive hearing loss remained
at the two-year follow-up.
Discussion
This case of FD presents the unusual association of two
different complex audiological diseases: otosclerosis
combined with SHL. Otosclerosis is a well-defined entity
and presents two different treatment options. Medical
therapy for otosclerosis can slow down the progression
of hearing loss, but the only possible cure to restore
hearing is a surgical stapedotomy [7]. As stated before,
the incidence of otosclerosis in patients with FD has
never been analyzed.
Several studies have indicated that progressive hearing
loss in patients with FD comprises 50% of the morbidity,
but only one study showed an SHL incidence of 11.8%
in men with FD [8]. Conti and Sergi [9] reported hear-
ing loss and vestibular function disorders in a cohort of
14 patients and a high incidence of sudden onset or
progression (or both) of symptoms. Hajioff and collea-
gues [10] studied 15 patients and also reported some
cases of conductive hearing loss.
More recently, two large studies on hearing loss in
patients with FD and on the effect of ERT have been
published. Hegemann and colleagues [11] analyzed the
audiograms of 86 patients and found that hearing in
patients with FD is significantly impaired with respect to
the age-matched general population and that this leads
to clinically relevant hearing impairment in 16% of
cases.
Hearing loss in patients with FD typically involves all
frequencies and appears to be more rapidly progressing
than the hearing loss associated with normal aging. In
men, residual enzyme activity of greater than 1.5%
appears to have a protective function, and ERT can sta-
bilize and possibly improve progressive hearing loss but
has no proven effect on preventing SHL [8]. Ries and
colleagues [8] described a positive association between
Figure 3 Audiogram of the second crisis. Hearing function is decreased for frequencies of 2 to 8 kHz. The air-bone gap remains unchanged.
Blue cross, left ear conduction; blue open arrow, left ear bone conduction; blue square, left ear conduction with narrow band note masking on
the opposite ear; blue triangle, left ear bone conduction with narrow band note masking on the opposite ear; red circle, right ear air
conduction; red open arrow, right ear bone conduction.
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and cerebrovascular and renal damage, suggesting a
combined neuropathic and vascular etiology of the dis-
ease. However, only a few data concerning treatment of
SHL in patients with FD are available.
ERT was successful for improving and stabilizing renal
function in our patient. Consistent with what is stated
in the literature, areas not responsive to ERT were the
central nervous system and the auditory apparatus.
Conclusions
As this case report demonstrates, there is only a partial
and transient beneficial effect of ERT and hyperbaric
oxygen treatment combined with corticotherapy and
pentoxifylline for hearing loss in patients with FD. As
there is no international consensus on treatment of SHL
[12] (particularly in patients with FD), the administered
therapy is the standard therapy for SHL, and the results
obtained in our case were at their best for the first treat-
ment course, whereas partial regression of the symp-
toms occurred on the second occasion. Although SHL
in patients with FD is rarely described, the symptoms
are consistent with the vascular alterations caused by
the disease in other areas. The incidence of SHL may be
underestimated.
The mechanism of progressive SHL in patients with
FD remains unclear. It has been suggested that globo-
triaosylceramide accumulation in vascular endothelium,
decreased numbers of spiral ganglion cells [13], long-
term obstruction of cranial vessels by dolicho-ectasic
arteries because of the local deposition of glycosphingo-
lipids into the wall of arteries, and atrophy of the stria
vascularis and spiral ligament might concur with the
genesis of otoneurological symptoms [14].
Figure 4 Partial recovery of high-frequency hearing three months after the onset of the second crisis. Blue cross, left ear conduction;
blue open arrow, left ear bone conduction; blue square, left ear conduction with narrow band note masking on the opposite ear; blue triangle,
left ear bone conduction with narrow band note masking on the opposite ear; red circle, right ear air conduction; red open arrow, right ear
bone conduction.
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even in otherwise healthy patients because the involved
anatomical structures may be evaluated only partially in
vivo. Patients with recurrent SHL usually present with
punctiform cerebral white matter lesions representing
microvascular brain damage, as is the case in patients
with FD.
To the best of our knowledge, no previous description
of otosclerosis in association with FD is available. We
could not find an obvious link between otosclerosis and
FD, as hypervascularization has been described for oto-
sclerosis in contrast to the microvascular damage seen
in FD. However, the involved structures are the same
and the spiral ligament has been described in both oto-
sclerosis and FD atrophy of the stria vascularis [14,15].
Further structured studies are necessary to identify the
underlying mechanism of inner-ear involvement in
patients with FD. Also, a careful follow-up is essential to
evaluate the degree of cochlear involvement, understand
the fundamental pathophysiological mechanisms, and
prevent SHL and the irreversible progression of hearing
damage in patients who have already undergone ERT.
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